[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 1996

Comparative Intravitreal Antibiotic Therapy for Experimental Enterococcus faecalis Endophthalmitis

Author Affiliations

From The Ocular Microbiology Laboratory, The Wilmer Ophthalmological Insitute, The Johns Hopkins University School of Medicine, Baltimore, Md.

Arch Ophthalmol. 1996;114(1):61-65. doi:10.1001/archopht.1996.01100130057009

Objective:  To evaluate the most effective intravitreal antibiotic treatment of vancomycin-sensitive and -resistant Enterococcus faecalis endophthalmitis.

Design:  Animal experiment.

Setting:  Seventy-eight New Zealand white rabbits received an intravitreal injection of 105 vancomycin-sensitive or -resistant E faecalis organisms in one eye. Infections were allowed to proceed 3 hours before dividing animals randomly into the following treatment groups (n=6, each): the vancomycin-sensitive E faecalis model—(1) vancomycin (1 mg/0.1 mL), (2) combined vancomycin (1 mg/0.1 mL) and amikacin (0.4 mg/0.1 mL), (3) combined vancomycin (1 mg/0.1 mL) and gentamicin (0.1 mg/0.1 mL), (4) combined vancomycin (1 mg/0.1 mL) and ceftazidime (2 mg/0.1 mL), (5) combined ampicillin (5 mg/0.1 mL) and gentamicin (0.1 mg/0.1 mL), and (6) pristinamycin (1 mg/0.1 mL); and the vancomycin-resistant E faecalis model—(1) same as above, excluding group 4. Control groups received sterile balanced salt solution. Twenty-four hours following intravitreal treatment, vitreous humor was collected for quantitative bacteriological studies.

Results:  Intravitreal therapy with combined vancomycin and amikacin provided the most effective reduction of vancomycin-sensitive E faecalis organisms compared with combined vancomycin and gentamicin therapy (P=.10, Wilcoxon's rank sum test) or any other treatment group (P<.01, Wilcoxon's rank sum test). For vancomycin-resistant E faecalis endophthalmitis model, the combined ampicillin and gentamicin therapy was the most effective, followed by the combined vancomycin and amikacin therapy (P<.01, Wilcoxon's rank sum test).

Conclusions:  Treatment with intravitreal vancomycin plus amikacin and with intravitreal ampicillin plus gentamicin provide an effective bactericidal therapy for severe experimental vancomycin-sensitive and -resistant E faecalis endophthalmitis, respectively.

Murray BE.  The life and times of the Enterococcus . Clin Microbiol Rev . 1990;3:46-65.
Mollering RC Jr.  Enterococcus species, Streptococcus bovis, and Leuconostoc species . In: Mandell JL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principle and Practice of Infectious Disease . 4th ed. New York, NY: Churchill Livingstone Inc; 1995:1826-1835.
Stevens SX, Jensen HG, Jett BD, Gilmore MS.  A hemolysin-encoding plasmid contributes to bacterial virulence in experimental Enterococcus faecalis endophthalmitis . Invest Ophthalmol Vis Sci . 1992;33:1650-1656.
Fisch A, Salvanet A, Prazuck T, et al.  Epidemiology of infective endophthalmitis in France . Lancet . 1991;338:1373-1376.
Olson JC, Flynn HW Jr, Forster RK, Culbertson WW.  Results in the treatment of postoperative endophthalmitis . Ophthalmology . 1983;90:692-699.Article
Weber DJ, Hoffman KL, Thoft RA, Baker AS.  Endophthalmitis following intraocular lens implantation: report of 30 cases and review of the literature . Rev Infect Dis . 1986;8:12-20.Article
Affeldt JC, Flynn HW Jr, Forster RK, Mandelbaum S, Clarkson JG, Jarus GD.  Microbial endophthalmitis resulting from ocular trauma . Ophthalmology . 1987;94:407-413.Article
Pavan PR, Oteiza EE, Hughes BA, Avni A.  Exogenous endophthalmitis initially treated without systemic antibiotics . Ophthalmology . 1994;101:1289-1297.Article
Diamond JC.  Intraocular management of endophthalmitis . Arch Ophthalmol . 1981;99:96-99.Article
Driebe WT Jr, Mandelbaum S, Forster RK, Schwartz LK, Culbertson WW.  Pseudophakic endophthalmitis . Ophthalmology . 1986;93:442-448.Article
Mandelbaum S, Forster RK, Gelender H, Culbertson W.  Late-onset endophthalmitis associated with filtering blebs . Ophthalmology . 1985;92:964-972.Article
Katz LJ, Cantor LB, Spaeth GL.  Complications of surgery in glaucoma . Ophthalmology . 1985;92:959-963.Article
Uchio E, Inamura M, Okada K, Hatano H, Saeki K, Ohno S.  A case of endogenous Enterococcus faecalis endophthalmitis . Jpn J Ophthalmol . 1992;36:215-221.
Campos JM, Howard BJ.  Streptococci and related organisms . In: Howard BJ, Keiser JF, Smith TF, Weissfeld AS, Tilton RC, eds. Clinical and Pathogenic Microbiology . 2nd ed. St Louis, Mo: Mosby—Year Book; 1994;10:262-267.
Shlaes DM, Binczewski B.  Enterococcal resistance to vancomycin and related cyclic glycopeptide antibiotics . Eur J Clin Microbiol Infect Dis . 1990;9:106-110.Article
Mederski-Samoraj BD, Murray BE.  High-level resistance to gentamicin in clinical isolates of enterococci . J Infect Dis . 1983;147:751-757.Article
Gordon S, Swenson JM, Hill BC, et al.  Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States . J Clin Microbiol . 1992;30:2373-2378.
National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests . 4th ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1990. Approved standard NCCLS document M2-A4.
National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically . 3rd ed. Villanova. Pa: National Committee for Clinical Laboratory Standards; 1993. Approved standard NCCLS document M7-A3.
Gray JW, Stewart D, Dedler SJ.  Species identification and antibiotic susceptibility testing of enterococci isolated from hospitalized patients . Antimicrob Agents Chemother . 1991;35:1943-1945.Article
Perri MB, Chow JW, Zervos MJ.  In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci . Diagn Microbiol Infect Dis . 1993;17:151-155.Article
Handwerger S, Perlman DC, Altarac D, McAuliffe V.  Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci . Clin Infect Dis . 1992;14:655-661.Article
Frieden TR, Munsiff SS, Low DE, et al.  Emergence of vancomycin-resistant enterococci in New York City . Lancet . 1993;342:76-79.Article
Zervos MJ, Kauffman CA, Therasse PM, Bergman AG, Mikesell TS, Schaberg DR.  Nosocomial infection by gentamicin-resistant Streptococcus faecalis . Ann Intern Med . 1987;106:687-691.Article
Mederski-Samoraj BD, Murray BE.  High-level resistance to gentamicin in clinical isolates of enterococci . J Infect Dis . 1983;147:751-757.Article
Moellering RC Jr, Korzeniowski OM, Sande MA, Wennersten CB.  Species-specific resistance to antimicrobial synergism in Streptococcus faecium and Streptococcus faecalis . J Infect Dis . 1979;140:203-208.Article
Handwerger S, Pucci MJ, Volk KJ, Liu J, Lee MS.  Vancomycin-resistant Leuconostoc mesenteroides and Lactobacillus casei synthesize cytoplasmic peptidoglycan precursors that terminate in lactate . J Bacteriol . 1994;176:260-264.
Sande MA, Mandell GL.  Antimicrobial agents . In: Gilman AG, Goodman LS, Gilman A, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics . 7th ed. New York, NY: Macmillan Publishing Co Inc; 1985:1192-1193.
Harwick HJ, Kalmanson GM, Guze LB.  In vitro activity of ampicillin or vancomycin combined with gentamicin or streptomycin against enterococci . Antimicrob Agents Chemother . 1973;4:383-387.Article
Mollering RC Jr.  The Garrod Lectures: the Enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options . J Antimicrob Chemother . 1991;28:1-12.Article
Watanakunakorn C, Bakie C.  Synergism ofvancomycin-gentamicin and vancomycin-streptomycin against enterococci . Antimicrob Agents Chemother . 1973;4:120-124.Article
Donahue S, Kowalski RP Ms, Eller AW, DeVaro JM, Jewart BH.  Empiric treatment of endophthalmitis . Arch Ophthalmol . 1994;112:45-47.Article
Campochiaro PA, Lim JI.  Aminoglycoside toxicity in treatment of endophthalmitis . Arch Ophthalmol . 1994;112:48-53.Article
Verma L, Arora R, Sachedev MS.  Macular infarction after intravitreal injection of amikacin . Can J Ophthalmol . 1993;28:241-243.
Kumar H, Ahuja S, Kumar A.  Macular infarction after intravitreal amikiacin . Ann Ophthalmol . 1993;25:262-263.
Campochiaro PA, Green WR.  Toxicity of intravitreous ceftazidime in primate retina . Arch Ophthalmol . 1992;110:1625-1659.Article
Jay WM, Fishman P, Aziz M, Shockley RK.  Intravitreal ceftazidime in a rabbit model: dose- and time-dependent toxicity and pharmacokinetics analysis . J Ocul Pharmacol . 1987;3:257-262.Article
Barza M, Lynch E, Baum JL.  Pharmacokinetics of newer cephalosporins after subconjunctival and intravitreal injection in rabbits . Arch Ophthalmol . 1993;111:121-125.Article
Fass RJ.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin against staphylococci, streptococci, and enterococci . Antimicrob Agents Chemother . 1991;35:553-559.Article
Pechere JC.  In vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci . J Antimicrob Chemother . 1992;30:15-18.Article
Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC Jr.  In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms . Antimicrob Agents Chemother . 1993;37:598-601.Article
Appelbaum PC, Splangler SK, Jacobs MR.  Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP 59500, biapenem, trospectomycin, and piperacillin/tazobactam . J Antimicrob Chemother . 1993;32:223-231.Article
Edberg SC, Hardalo CJ, Kontnick C, Campbell S.  Rapid detection of vancomycin-resistant enterococci . J Clin Microbiol . 1994;32:2182-2184.